The slip
PARKINSON RECEIPTno. 9926
25 Oct 2026, 17:00 UTColigodendrocytes, braak
predictionRNF13 in oligodendrocytes tracks Braak Lewy-body stage
registeredb89fc3b74d532cee
discovery+0.59 p=0.096 n=9
replication+0.59 p=0.095 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.59, p 0.096)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTe0bbd841e41a509fdb3cfd04…
follows d4e49e10c1d4…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 9926: RNF13 in oligodendrocytes, braak
- power
- full sample +0.56 (p 0.017, n 18), 95% CI +0.12 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.58 (p 0.013, n 18). holds up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.68 (p 0.0017, n 18). not the mix.
- skeptic
- leave-one-out range +0.50 to +0.63, sign flips 0; without severely affected donors +0.56 (p 0.017, n 18). robust.
- cell type
- strongest in dopamine neurons: +0.72 (p 8.2e-4, n 18) vs +0.56 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF13 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RNF13 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 2.2e-4)